newsfilter
← Latest News
GlobeNewswire·

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to dateTopline data